[Effects of RelA antisense oligonucleotide on apoptosis of ovarian cancer cells COC1].
OBJECTIVE
To evaluate the effects of RelA antisense oligonucleotide on apoptosis of ovarian cancer cells.


METHODS
COC1 cell line was treated with RelA antisense oligonucleotide combining with tumor necrosis factor (TNF)-alpha or paclitaxel at appropriate concentrations and duration. The apoptosis and RelA activation of ovarian cancer line COC1 cell were measured by indirect immunofluorescence, Western blot, flow cytometric analysis, DNA ladder assay.


RESULTS
The apoptosis increased obviously in COC1 rells if treated by RelA antisense oligonucleotide combining with paclitaxel 50 micromol/L than paclitaxel 50 micromol/L only (27.4 +/- 0.5)% vs (12.3 +/- 0.6)% (P < 0.01), when treated 12 hs; (31.7 +/- 0.3)% vs (13.0 +/- 0.5)% (P < 0.01) when treated 24 hs. The apoptosis was also increased obviously in COC1 cells if treated by RelA antisense oligonucleotide combining with TNF-alpha 50 microgram/L than TNF-alpha 50 microgram/L alone. (30.8 +/- 0.3)% vs (13.2 +/- 0.4)% (P < 0.01).


CONCLUSIONS
RelA antisense oligonucleotide may induce apoptosis susceptibility of COC1 cells to TNF-alpha or paclitaxel.
Department of Obstetrics and Gynecology, Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University, Wuhan, 430030, China.
Changyu
C
Wang
Fang
F
Hu
Yunping
Y
Lu
Shixuan
S
Wang
Ding
D
Ma
D017209:Apoptosis / Q000187:drug effects*; D005260:Female; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D051996:Transcription Factor RelA; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D016328:NF-kappa B; D016376:Oligonucleotides, Antisense; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D017239:Paclitaxel